» Articles » PMID: 23652522

Effect of Long-detection Interval Vs Standard-detection Interval for Implantable Cardioverter-defibrillators on Antitachycardia Pacing and Shock Delivery: the ADVANCE III Randomized Clinical Trial

Overview
Journal JAMA
Specialty General Medicine
Date 2013 May 9
PMID 23652522
Citations 114
Authors
Affiliations
Soon will be listed here.
Abstract

Importance: Using more intervals to detect ventricular tachyarrhythmias has been associated with reducing unnecessary implantable cardioverter-defibrillator (ICD) therapies.

Objective: To determine whether using 30 of 40 intervals to detect ventricular arrhythmias (VT) (long detection) during spontaneous fast VT episodes reduces antitachycardia pacing (ATP) and shock delivery more than 18 of 24 intervals (standard detection).

Design, Setting, And Participants: Randomized, single-blind, parallel-group trial that enrolled 1902 primary and secondary prevention patients (mean [SD] age, 65 [11] years; 84% men; 75% primary prevention ICD) with ischemic and nonischemic etiology undergoing first ICD implant at 1 of 94 international centers (March 2008-December 2010).

Interventions: Patients were randomized 1:1 to programming with long- (n = 948) or standard-detection (n = 954) intervals.

Main Outcomes And Measures: Total number of ATPs and shocks delivered for all episodes (primary outcomes) and inappropriate shocks, mortality, and syncopal rate (secondary outcomes).

Results: During a median follow-up of 12 months (interquartile range, 11-13), long-detection group had 346 delivered therapies (42 therapies per 100 person-years, 95% CI, 38-47) vs 557 in the standard-detection group (67 therapies per 100 person-years [95% CI, 62-73]; incident rate ratio [IRR], 0.63 [95% CI, 0.51-0.78]; P < .001). The long- vs the standard-detection group experienced 23 ATPs per 100 person-years (95% CI, 20-27) vs 37 ATPs per 100 person-years (95% CI, 33-41; IRR, 0.58 [95% CI, 0.47-0.72]; P < .001); 19 shocks per 100 person-years (95% CI, 16-22) vs 30 shocks per 100 person-years (95% CI, 26-34; IRR, 0.77 [95% CI, 0.59-1.01]; P = .06), with a significant difference in the probability of therapy occurrence (P < .001); and a reduction in first occurrence of inappropriate shock (5.1 per 100 patient-years [95% CI, 3.7-6.9] vs 11.6 [95% CI, 9.4-14.1]; IRR, 0.55 [95% CI, 0.36-0.85]; P = .008). Mortality (5.5 [95% CI, 4.0-7.2] vs 6.3 [95% CI, 4.8-8.2] per 100 patient-years; HR, 0.87; P = .50) and arrhythmic syncope rates (3.1 [95% CI, 2.6-4.6] vs 1.9 [95% CI, 1.1-3.1] per 100 patient-years; IRR, 1.60 [95% CI, 0.76-3.41]; P = .22) did not differ significantly between groups.

Conclusions And Relevance: Among patients receiving an ICD, the use of a long- vs standard-detection interval resulted in a lower rate of ATP and shocks, and inappropriate shocks. This programming strategy may be an appropriate alternative.

Trial Registration: clinicaltrials.gov Identifier: NCT00617175.

Citing Articles

The Role of Subcutaneous ICDs in the Prevention of Sudden Cardiac Death.

John L, Karimianpour A, Gold M US Cardiol. 2024; 15:e19.

PMID: 39720500 PMC: 11664769. DOI: 10.15420/usc.2021.01.


Clinical Decision Making and Technical Approaches in Implantable Cardioverter-Defibrillator Procedures: A Step by Step Critical Appraisal of Literature.

Roseboom E, Smit M, Groenveld H, Rienstra M, Maass A Rev Cardiovasc Med. 2024; 25(11):403.

PMID: 39618862 PMC: 11607494. DOI: 10.31083/j.rcm2511403.


Optimal Timing of Cardioverter-Defibrillator Implantation in Patients with Left Ventricular Dysfunction after Acute Myocardial Infarction.

Ursaru A, Costache I, Petris A, Haba M, Mitu O, Crisan A Rev Cardiovasc Med. 2024; 23(4):124.

PMID: 39076214 PMC: 11273764. DOI: 10.31083/j.rcm2304124.


Effects of Irradiation During Computed Tomography Scanning on the Function of Implantable Cardioverter-defibrillators.

Nishikawa Y, Fujimoto N, Kurata T, Sasou T, Yamazaki A, Ichikawa Y J Innov Card Rhythm Manag. 2024; 15(7):5936-5944.

PMID: 39011460 PMC: 11238888. DOI: 10.19102/icrm.2024.15073.


Implantable Cardioverter Defibrillator Tachycardia Therapies: Past, Present and Future Directions.

Leong A, Arnold A, Whinnett Z J Cardiovasc Dev Dis. 2024; 11(3).

PMID: 38535115 PMC: 10970811. DOI: 10.3390/jcdd11030092.